Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Epizyme, Inc.
  6. Company
    EPZM   US29428V1044

EPIZYME, INC.

(EPZM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Epizyme, Inc.
Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule inhibitors of other chromatin modifying proteins (CMPs). The Company's lead product candidate, tazemetostat, is a potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2) histone methyltransferases (HMT), an enzyme that plays an important role in various cancers. The Company is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), and one Phase I study in children with molecularly defined solid tumors. The Company owns the global development and commercialization rights to tazemetostat outside of Japan.

Number of employees : 304 people.
Sales per Business
2020
Novel Epigenetic Therapies11.4772.8%
Collaboration4.2927.2%
USD in Million
Sales per region
20192020Delta
United States23.80100%15.76100% -33.77%
USD in Million
Managers
Name Title Age Since
Grant C. Bogle President, Chief Executive Officer & Director 62 2021
Matthew E. Ros Chief Financial Officer 54 2021
Shefali Agarwal, Dr. Executive VP, Chief Medical & Development Officer 46 2021
Jeffery L. Kutok, Dr. Chief Scientific Officer & Executive VP 53 2020
Carl Samuel Goldfischer, Dr. Independent Director 61 2009
David M. Mott Chairman 54 2016
Andrew R. Allen, Dr. Independent Director 53 2014
Kenneth M. Bate Independent Director 69 2014
Kevin Conroy Independent Director 54 2017
Victoria M. Richon, Dr. Independent Director 61 2019
Members of the board
Name Title Age Since
David M. Mott Chairman 54 2016
Carl Samuel Goldfischer, Dr. Independent Director 61 2009
Andrew R. Allen, Dr. Independent Director 53 2014
Kenneth M. Bate Independent Director 69 2014
Kevin Conroy Independent Director 54 2017
Michael F. Giordano, Dr. Director 62 2018
Grant C. Bogle President, Chief Executive Officer & Director 62 2021
Victoria M. Richon, Dr. Independent Director 61 2019
Pablo Legorreta Director 56 2019
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 102,249,517 79,089,325 77.3% 0 0.0% 77.3%
Stock B 0 338,000 0 0.0% 0 0.0%
Shareholders
NameEquities%
PRIMECAP Management Co. 15,287,477 15.0%
RP Management LLC (Investment Management) 9,166,667 8.97%
Redmile Group LLC 8,515,060 8.33%
The Vanguard Group, Inc. 7,653,395 7.49%
Palo Alto Investors LP 6,856,513 6.71%
SSgA Funds Management, Inc. 5,595,705 5.47%
NEA Management Co. LLC 4,377,518 4.28%
Kleiner Perkins Caufield & Byers LLC 3,838,166 3.75%
Bay City Capital LLC 3,380,951 3.31%
Consonance Capital Management LP 3,304,918 3.23%
Company contact information
Epizyme, Inc.
400 Technology Square
4th floor
Cambridge, MA 02139

Phone : +1.617.229.5872
Fax : +1.617.349.0707
Web : http://www.epizyme.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Epizyme, Inc.
Sector Bio Therapeutic Drugs